Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-OX40 agonist monoclonal antibody HFB301001

An agonistic human immunoglobulin G1 (IgG1) monoclonal antibody that recognizes the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunomodulatory and antineoplastic activities. Upon administration, anti-OX40 agonist monoclonal antibody HFB301001 selectively targets and binds to a unique epitope on OX40, and activates OX40 without competing with the endogenous OX40 ligand (OX40L; tumor necrosis factor ligand superfamily member 4; TNFSF4). This may induce the proliferation of memory and effector T lymphocytes and inhibit the function of T-regulatory cells (Tregs) in the tumor microenvironment (TME), thereby enhancing anti-tumor immune responses and preventing Tregs-mediated immune suppression. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T lymphocytes and plays an essential role in T-cell activation and differentiation. HFB301001 does not lead to a downregulation of OX40 following the co-stimulation of T cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:agonistic anti-OX40 monoclonal antibody HFB301001
Code name:HFB 301001
HFB-301001
HFB301001
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search